ArticleJournal of bacteriology2017
Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
Article in Journal of bacteriology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Detection and identification of pathogens using agents targeting the bacterial cell wall.Folia microbiologica · 2026Review
- Gallium Resistance inApplied microbiology (Basel, Switzerland) · 2025Article
- The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis.Scientific reports · 2023Article
- DivIVA Interacts with the Cell Wall Hydrolase MltG To Regulate Peptidoglycan Synthesis in Streptococcus suis.Microbiology spectrum · 2023Article
- Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS.Scientific reports · 2022Article
- Molecular dynamics simulations of the secondary-binding site in disaccharide-modified glycopeptide antibiotics.Scientific reports · 2022Article
- Virulence alterations in staphylococcus aureus upon treatment with the sub-inhibitory concentrations of antibiotics.Journal of advanced research · 2021Review
- Molecular Dynamics Simulation of Atomic Interactions in the Vancomycin Binding Site.ACS omega · 2021Article
- Organoarsenicals inhibit bacterial peptidoglycan biosynthesis by targeting the essential enzyme MurA.Chemosphere · 2020Article
- Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.Pathogens (Basel, Switzerland) · 2020Review
- Fluorescence assay to predict activity of the glycopeptide antibiotics.The Journal of antibiotics · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Oritavancin is a lipoglycopeptide antibiotic that exhibits potent activities against vancomycin-resistant Gram-positive pathogens. Oritavancin differs from vancomycin by a hydrophobic side chain attached to the drug disaccharide, which forms a secondary binding site to enable oritavancin binding to the cross-linked peptidoglycan in the cell wall. The mode of action of secondary binding site was investigated by measuring the changes in the peptidoglycan composition of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.